Previously Published Studies

Previously published studies in which patients treated at Southwest Veterinary Oncology were included:

 

Vail DM, von Euler H,  Rusk AW, Barber L, Clifford R, Elmslie R, Fulton L, Hirschberger J, Klein M, et al.  A Randomized Trial Investigating the Efficacy and Safety of Water Soluble Micellar Paclitaxel (Paccal Vet) for Treatment of Nonresectable Grade 2 or 3 Mast Cell Tumors in Dogs. J Vet Intern Med 2012.

 

Grosenbaugh DA, Leard T, Bergman PJ, Klein MK, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 2011 72:1631-8.

 

Beaver LM, Strottner G, Klein MK.  Response rate after administration of a single dose of  doxorubicin in dogs with B-cell or T-cell lymphoma:  41 cases (2006-2008). J Am Vet Med Assoc. 2010 Nov 1;237(9):1052-5.

 

Charney SC, Lutz WR, Klein, MK, Jones PD.  Evaluation of a head-repositioner and Z-plate system for improved accuracy of dose delivery. Vet Radiol Ultrasound.  2009 May-Jun 50(3):323-329.

 

Haney SM, Beaver L, Turrel J, Clifford CA, Klein MK, et al.  Survival  analysis of 97 cats with nasal lymphoma: a multi-institutional retrospective study (1986-2006). J Vet Intern Med. 2009 Mar-Apr;23(2)287-94.

 

Vail DM, Rodabaugh JS, Conder GA, Klein MK, et al  Efficacy of injectable maropitant (Cerenia) in a randomized clinical trial for prevention and treatment of cisplatin-induced emesis in dogs presented as veterinary patient. Vet Comp Oncol 2007 5:38-46.

 

London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, et al.  Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009 Jun1;15(11):3856-65.

 

Moore AS, Dernell WS, Ogilvie GK, Kristal O, Elmslie R, Kitchell B, Susaneck S, Rosenthal R, Klein MK, Obradovich J, Legendre A, et al.  Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs:  a randomized, double-blind, placebo-controlled study. Am J Vet Res. 2007 Nov;68(11):1246-1251.

 

Henry CJ, Downing S, Rosenthal RC, Klein MK, et al.  Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. Am J Vet Research. 2007 Nov;68(11):1246-1251.
LeBlanc AK, LaDue TA, Turrel JM, Klein MK.  Unexpected toxicity following the use of gemcitabine as a radiosensitizer in head and neck carcinomas:  a veterinary radiation therapy group pilot study. Vet Radio Ultrasound.  2004 Sep-Oct;45(5):466-470.

 

LaDue T, Klein MK.  Toxicity criteria of the veterinary radiation therapy oncology group. Vet Radiol Ultrasound. 2001 Sep-Oct;42(5):475-476.

 

Bergman PJ, MacEwen EG, Kurzman ID, Henry CJ, Hammer AS, Knapp DW, Hale A, Kurth SA, Klein MK, Klausner J, Morris AM, McCaw D, Straw RC, and Withrow SJ.  Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991-1993). J Vet Intern Med 10:76-81, 1996.